shot-button
Maharashtra Elections 2024 Maharashtra Elections 2024
Home > News > India News > Article > Central Drugs Standard Control Organisation extends Covaxin shelf life to 12 months

Central Drugs Standard Control Organisation extends Covaxin shelf life to 12 months

Updated on: 03 November,2021 06:43 PM IST  |  New Delhi
ANI |

The company said, 'Extension is based on the availability of additional stability data, which was submitted to CDSCO. The extension has been communicated to our stakeholders'

Central Drugs Standard Control Organisation extends Covaxin shelf life to 12 months

This picture has been used for representational purpose

Hyderabad-based Bharat Biotech's Covid-19 vaccine Covaxin has received an extension of shelf life for up to 12 months from the date of manufacturing India's pharmaceuticals and medical regulatory body.


"The Central Drugs Standard Control Organisation (CDSCO) has approved the extension of shelf life of COVAXIN up to 12 months, from the date of manufacture," said Bharat Biotech in a statement posted by the biotechnology company on its official Twitter handle.


The company said, "Extension is based on the availability of additional stability data, which was submitted to CDSCO. The extension has been communicated to our
stakeholders." Meanwhile, the World Health Organisation (WHO) granted approval for Emergency Use Listing (EUL) for Covaxin.


It was approved on the recommendation of the Technical Advisory Group (TAG) for Emergency Use Listing (TAG-EUL), an independent advisory panel that provides
recommendations to WHO on whether a Covid-19 vaccine can be listed for emergency use under the EUL procedure.

Covaxin has demonstrated 77.8 per cent effectiveness against symptomatic Covid-19 and 65.2 per cent protection against the new Delta variant. Bharat Biotech said that it concluded the final analysis of Covaxin efficacy from Phase 3 trials. Bharat Biotech's Covaxin and AstraZeneca and Serum Institute's Covishield are the two
widely used vaccines in India. The WHO has so far approved Covid-19 vaccines of Pfizer-BioNTech, AstraZeneca-SK Bio/Serum Institute of India, Johnson & Johnson - Janssen, Moderna, and Sinopharm for emergency use. Meanwhile, India's cumulative vaccination coverage crossed 107 crore.

Also Read: Mumbai: No Covid-19 vaccination at civic, govt-run centres for 4 days

This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever.

"Exciting news! Mid-day is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest news!" Click here!

Register for FREE
to continue reading !

This is not a paywall.
However, your registration helps us understand your preferences better and enables us to provide insightful and credible journalism for all our readers.

Mid-Day Web Stories

Mid-Day Web Stories

This website uses cookie or similar technologies, to enhance your browsing experience and provide personalised recommendations. By continuing to use our website, you agree to our Privacy Policy and Cookie Policy. OK